GLP-1s for Older Adults: The Muscle Question and Medicare Access

Two things changed for older adults at roughly the same time. Medicare opened a pathway to weight-loss medication that had not previously existed, and the evidence on muscle loss sharpened in a way that matters more after 65 than at any earlier age. Both belong in the same conversation.

Why Age Changes the Calculation

Sarcopenia — age-related loss of skeletal muscle mass and function — is common and consequential. Reporting from the Endocrine Society notes that up to half of adults over age 80 experience sarcopenia. Muscle loss in this group is not primarily a cosmetic or metabolic concern; it predicts falls, fractures, loss of independence, and mortality.

Layering an intervention that causes some lean mass loss onto that baseline is where the caution originates. Research presented at ENDO 2025 was direct about it: "Older adults and women may be more likely to lose muscle on semaglutide, but eating more protein may help protect against this."

A 2026 review in the American Journal of Medicine examining sarcopenia in the era of GLP-1 receptor agonists made a related point worth keeping in view — sarcopenia occurs across a wide spectrum of clinical settings and is not limited to older adults. Age raises the risk; it does not monopolize it.

What Protects Muscle After 65

The mitigations are the same as in younger patients, but the margin for neglecting them is smaller.

Protein intake. The ENDO research points directly at this. Older adults also experience anabolic resistance — meaning they require more protein per meal than younger adults to trigger the same muscle protein synthesis response. Combine that with GLP-1 appetite suppression and the shortfall risk is substantial. Distributing protein across meals, prioritizing it first at each meal, and using liquid sources when solid volume is poorly tolerated all become more important, not less.

Resistance training. The loading signal is what tells the body to retain muscle in a deficit. Older adults respond to resistance training — the capacity to build and retain muscle is reduced with age, not absent. Programming should be appropriate to baseline function and mobility, which usually means supervision rather than self-direction.

Rate of loss. Slower is better for body composition at any age, and the argument strengthens here. A moderated titration pace preserves more lean mass than a rapid one.

Full detail is in our guide to GLP-1 muscle loss prevention, and practical eating strategies in what to eat on GLP-1.

Monitoring That Matters More Here

• Grip strength — a validated, simple correlate of overall muscle function
• Gait speed and chair-rise — functional measures that predict independence better than weight does
• Falls history — any increase deserves attention as a possible signal
• Body composition where available, rather than scale weight alone
• Nutritional adequacy — including micronutrients, given reduced overall intake

Scale weight is a particularly poor metric in this population because it cannot distinguish the loss you want from the loss you do not.

Medicare Access in 2026

Medicare historically excluded weight-loss medications from Part D. The Medicare GLP-1 Bridge changed that for eligible beneficiaries, with a $50 copayment per 30-day supply of the weight-loss medication.

Two details catch people out. The $50 covers medication only — healthcare services, including visit costs, are separate. And coverage follows the product and indication, not the molecule: Mounjaro, for example, is covered by some plans for type 2 diabetes but not weight loss and is excluded from the 2026 Bridge, while Zepbound is the weight-loss tirzepatide product. Eligible Part D beneficiaries may also access Foundayo (orforglipron) at $50/month beginning as soon as July 1, 2026.

Medicare.gov provides an eligibility questionnaire for the program. Full detail is in our guide to GLP-1 insurance coverage in 2026.

Other Age-Specific Considerations

• Polypharmacy. Delayed gastric emptying can alter absorption of other oral medications — relevant when a patient takes many.
• Dehydration risk. Older adults have blunted thirst perception and less physiological reserve. GI side effects causing volume depletion carry more consequence, particularly alongside reduced kidney function.
• Bone density. Rapid weight loss can affect bone mass, compounding existing osteoporosis risk.
• Comorbidity burden. The cardiometabolic benefits may be larger in this group precisely because baseline risk is higher — the calculus is not one-sided.

The Bottom Line

GLP-1 medications are not contraindicated by age, and older adults often carry the comorbidity burden that makes weight reduction most valuable. Medicare access has genuinely improved. But this is the population where the muscle question stops being theoretical.

The evidence points to a clear conclusion: if an older adult starts a GLP-1, protein adequacy and resistance training should be part of the prescription from day one, and monitoring should track function rather than scale weight. Treatment that reduces weight while costing independence is not a good outcome, and that trade is avoidable with attention.